Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04296890
Title A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

ovarian serous carcinoma

fallopian tube cancer

peritoneum cancer

Therapies

Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL


No variant requirements are available.